Literature DB >> 4903552

[Treatment of multiple myeloma with a new cytostatic agent: gamma-l-methyl-5-bis-(beta-chlorethyl)-amino-benzimidazolyl-(2)-butyric acid hydrochloride].

G Anger, P Hesse, H Baufeld.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 4903552     DOI： 10.1055/s-0028-1110470

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN： 0012-0472            Impact factor:   0.628


× No keyword cloud information.
  4 in total

Review 1.  Novel Agents in Multiple Myeloma.

Authors:  Raphaël Szalat; Nikhil C Munshi
Journal:  Cancer J       Date:  2019 Jan/Feb       Impact factor: 3.360

2.  Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block.

Authors:  Varsha Gandhi; Jan A Burger
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

3.  Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO).

Authors:  W Pönisch; P S Mitrou; K Merkle; M Herold; M Assmann; G Wilhelm; K Dachselt; P Richter; V Schirmer; A Schulze; R Subert; B Harksel; N Grobe; E Stelzer; M Schulze; A Bittrich; M Freund; R Pasold; Th Friedrich; W Helbig; D Niederwieser
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-10       Impact factor: 4.553

4.  Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin's lymphoma.

Authors:  Rudolf Weide
Journal:  Ther Clin Risk Manag       Date:  2008-08       Impact factor: 2.423
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.